Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Well, the glimmer of hope

<< Previous

Bullboard Posts

Next >>

Comment by StockingUp21on May 05, 2021 6:54pm

100 Views

Post# 33137552

RE:RE:RE:RE:RE:RE:Well, the glimmer of hope

this is an asset should be ours already! The holding company got their IP through trials on the back of us, and now they drag this out. Share price is fair for this circus.

Stoxxhp wrote:

Layth1990 wrote: I will not average down with this situation. when is the IP aquision ? winter ? we will have dilution most probably with IP and i will buy a bit. if phase 3 got postponed we are all fuc*ed and " no dilution as he stated in bio interview" will dilute us again for third time as cash is being burnt every sec.

Yes, there will be dillution, and in exchange ATE will be getting an asset, don't leave that part out of your complaint